Business
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer. The data from the fully enrolled study demonstrate preliminary evidence of clinical activity, including durable
About this update from Can-fite Biopharma Ltd.
[{"type":"image","alt":"Can-Fite BioPharma Ltd.","displaySize":"","headline":null,"caption":"Can-Fite BioPharma Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/58ba4a28406cb6448f12deb3b1c1ba75"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QYfbHRgMRgvY8wsgsUOyJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/58ba4a28406cb6448f12deb3b1c1ba75","width":300,"height":300}},"lazy":false},{"type":"text","content":"Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer.","length":394,"tagName":"p"},{"type":"text","content":"The data from the fully enrolled study demonstrate preliminary evidence of clinical activity, including durable disease stabilization in a heavily pretreated patient population, in addition to the previously reported favorable safety profile.","length":242,"tagName":"p"},{"type":"text","content":"Key findings include:","length":21,"tagName":"p"},{"type":"text","content":"· Stable disease observed in >30% of evaluable patients","length":88,"tagName":"p"},{"type":"text","content":"· Prolonged treatment duration includes one patient extending beyond 16 months.","length":109,"tagName":"p"},{"type":"text","content":"· 35% of patients remain on therapy and follow up","length":79,"tagName":"p"},{"type":"text","content":"· Favorable safety and tolerability profile consistent with prior reports","length":103,"tagName":"p"},{"type":"text","content":"The prolonged treatment duration observed in several patients suggests a potential for durable clinical benefit in this difficult-to-treat population.","length":150,"tagName":"p"},{"type":"text","content":"“As we continue to analyse the data, we are encouraged by the emerging signal of durable disease stabilization observed in this study,” said Pnina Fishman, Chairperson and Chief Scientific Officer of Can-Fite....